ReviewClinical and experimental immunology2005
New therapies for systemic lupus erythematosus.
Review in Clinical and experimental immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Trial
- Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Annals of the rheumatic diseases · 2007Trial
- Article
- Stem Cell Applications for Treatment of Cancer and Autoimmune Diseases: Its Promises, Obstacles, and Future Perspectives.Technology in cancer research & treatment · 2018Review
- Expression and clinical significance of the NEK7-NLRP3 inflammasome signaling pathway in patients with systemic lupus erythematosus.Journal of inflammation (London, England) · 2018Article
- Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort.Lupus science & medicine · 2018Article
- Report of an international symposium on narrowing the Gap in the treatment and study of SLE worldwide: minimum best practices in the management and monitoring of moderate to severe SLE and improving outcomes in constrained environments.Current reviews in musculoskeletal medicine · 2011Article
- Stem cells in clinical practice: applications and warnings.Journal of experimental & clinical cancer research : CR · 2011Review
- Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes.Clinical and experimental immunology · 2010Article
- Prednisone, lupus activity, and permanent organ damage.The Journal of rheumatology · 2009Article
- Haematopoietic SCT in autoimmune diseases in children: rationale and new perspectives.Bone marrow transplantation · 2008Review
- Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.Pathology, research and practice · 2008Review
- Autoimmune mechanisms in children with systemic lupus erythematosus.Current rheumatology reports · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past 40 years, prognosis for patients with systemic lupus erythematosus (SLE) has improved, with 10-year survival now approximately 90%. This is due probably to a combination of earlier disease diagnosis and diagnosis of milder disease, due in part to availability of multiple serological tests for SLE, use of steroids and other immunosuppressive agents, and availability of renal dialysis and transplantation. Despite this, however, the potential for significant morbidity and mortality remains in the group of patients with partially responsive or treatment resistant disease. More recently, advancements in the understanding of molecular mechanisms involved in the pathogenesis of SLE have translated to the development of novel therapies, offering possible alternatives to this patient cohort. Discussion of these pharmacological options and ongoing research forms the basis of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.